Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RER |
Synonyms | |
Therapy Description |
RER is a TGF-beta trivalent trap with avidity to TGF-beta1 and TGF-beta3, potentially inhibiting downstream TGF-beta signaling, cell migration, and cell proliferation (PMID: 27863384). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RER | RII-BGE-RII | TGFB inhibitor 5 | RER is a TGF-beta trivalent trap with avidity to TGF-beta1 and TGF-beta3, potentially inhibiting downstream TGF-beta signaling, cell migration, and cell proliferation (PMID: 27863384). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN del | prostate cancer | sensitive | RER | Preclinical | Actionable | In a preclinical study, RER treatment inhibited Tgf-beta and Akt pathways signaling, led to inhibition of tumor cell proliferation and tumorigenesis in a PTEN knock-out mouse model of prostate cancer (PMID: 27863384). | 27863384 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|